hit counter

Seletracetam for Seizure Rescue: Non-Benzodiazepine Alternative Revisited

MHD featured image for seletracetam as a possible non-benzodiazepine seizure rescue therapy.

A 2026 CNS Drugs review argues that seletracetam, an abandoned second-generation racetam antiseizure drug, may be unusually well suited for seizure rescue: early oral studies involved 171 participants, photosensitivity responses occurred in 32 of 36 exposures, and one intranasal named-patient use reduced reading-induced spike rate from 3.1/min to 1.6/min without sedation. Research Highlights Rescue-therapy rationale: …

Read more

Levetiracetam Range in Children: 2.82-24.37 mcg/mL TDM

MHD featured image for levetiracetam therapeutic drug monitoring in children with epilepsy.

A 2026 real-world study involving 1,174 children with epilepsy proposed a levetiracetam therapeutic drug monitoring range of 2.82-24.37 mcg/mL, much lower than commonly cited adult-style ranges, but the same data also warned against treating a drug level as a stand-alone seizure-control predictor. Research Highlights Lower pediatric range: Sun et al. proposed an observational levetiracetam range …

Read more

Levetiracetam After Stroke: 9 Fewer Deaths in Older Adults

MHD featured image for levetiracetam continuation, post-stroke seizure prevention, and 90-day survival in older adults.

A 2026 Medicare target-trial emulation found continued levetiracetam after acute ischemic stroke was associated with 53 vs. 62 deaths per 1,000 over 90 days, a risk difference of −9 deaths per 1,000 favoring continuation. Research Highlights Survival signal: continued levetiracetam after an initial month of post-stroke use was linked to 53 deaths per 1,000 vs. …

Read more